Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Long-Term Deferred Tax (2019 - 2024)

Eton Pharmaceuticals (ETON) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $404000.0 as the latest value for Q4 2024.

  • Quarterly Long-Term Deferred Tax rose 139.05% to $404000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $404000.0 through Dec 2024, up 139.05% year-over-year, with the annual reading at $404000.0 for FY2024, 139.05% up from the prior year.
  • Long-Term Deferred Tax hit $404000.0 in Q4 2024 for Eton Pharmaceuticals, up from $169000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $18.5 million in Q4 2021 to a low of $169000.0 in Q4 2023.
  • Historically, Long-Term Deferred Tax has averaged $6.4 million across 3 years, with a median of $404000.0 in 2024.
  • Biggest YoY gain for Long-Term Deferred Tax was 139.05% in 2024; the steepest drop was 139.05% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $18.5 million in 2021, then crashed by 99.09% to $169000.0 in 2023, then surged by 139.05% to $404000.0 in 2024.
  • Business Quant data shows Long-Term Deferred Tax for ETON at $404000.0 in Q4 2024, $169000.0 in Q4 2023, and $18.5 million in Q4 2021.